fashion -WSS

fashion

author：Wikipedia 2025-09-30 20:17:55 - browse：4

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Petition to FDA: Get the lead out of consumer hair dyes

WSS

DOJ reversal could clear way for Carroll's 1st lawsuit against Trump to proceed

Cognito secures funding to test medical device for Alzheimer's

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Biden launches a new push to limit health care costs

Medicare drug price negotiation’s day in court

New research casts further doubt on a common procedure used with IVF

explore

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Elizabeth Holmes on track for early release from her 11

How to save PrEP access — and even expand it

N.Y. state detects polio case, first in the U.S. since 2013

DIEP, the 'gold standard' of breast reconstruction, is under threat

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Hepatitis C has a cure — but many Americans still lack access to it

What to know about OceanGate, the company behind the missing Titanic submersible

Medicare details structure of new drug price negotiation program

It's time to get medical device identifiers over the finish line

focus

Lecanemab for Alzheimer's is coming. Is the health system ready?

Why 40% Americans with Parkinson’s don’t see a neurologist

Some dementia cases could be undiagnosed liver disease

The lessons of Aduhelm, an Alzheimer's drug that was not to be

New Ultima Genomics DNA sequencer can read genome for $100

Woodcock on FDA’s accelerated approval and her next chapter

entertainment

knowledge

hotspot

focus